Pfizer CFO Dave Denton to depart in August as company names interim finance chief

Pfizer said on Thursday that its chief financial officer, Dave Denton, will step down and leave the company on August 15, marking a leadership change in the drugmaker’s finance function. The company said Denton is departing to pursue an opportunity outside the pharmaceutical industry, according to multiple reports covering the announcement.

The planned exit was reported by Investing.com, Nasdaq and CNBC, all of which described the move as a departure from Pfizer rather than an immediate resignation. The timing gives the company several weeks to prepare for the transition before Denton’s final day. No further details about the new role were provided in the source material.

Pfizer also identified an interim replacement for the finance post. According to Nasdaq, Cecile Guegan will serve as interim finance chief after Denton leaves. The reports did not include additional information about Guegan’s current responsibilities or whether Pfizer has already started a search for a permanent successor.

The announcement places a fresh focus on Pfizer’s senior leadership at a time when investors continue to watch the company’s operating and financial direction closely. The finance chief role is central to the company’s capital allocation, budgeting and broader financial strategy, making any change in the position a notable event for shareholders and analysts. While the reports did not cite any operational issues linked to the departure, the move nonetheless adds another layer of transition at the top of the organization.

Market reaction to the news was negative in early trading, with Investing.com noting that Pfizer stock fell after the CFO departure was disclosed. The sources did not provide a percentage move or specific price level, but the reaction suggests investors viewed the leadership change as noteworthy. No other market-moving details were included in the reports, and the company did not announce any revision to its financial outlook in the material provided.

The reports also did not mention any changes to Pfizer’s broader management structure beyond the finance leadership transition. As presented, the announcement was limited to Denton’s upcoming departure, the stated reason for leaving and the naming of an interim finance chief. For now, the key issue for the company is the orderly handoff of duties before mid-August, with the market likely to remain attentive to any further updates on a permanent appointment.